Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Proteros Biostructures GmbH. (1/8/15). "Press Release: Proteros Enters into a Collaboration with Bayer to Develop New Cardiovascular Drug Compounds for an Integral Membrane Protein". Martinsried.

Organisation Organisation Proteros Biostructures GmbH
  Group Proteros (Group)
Products Product drug discovery services
  Product 2 cardiovascular drug
Index term Index term Bayer–Proteros: drug discovery services, 201501–201612 collab identification of cardiovascular compounds for integral membrane protein
Persons Person Reinemer, Peter (Proteros Biostructures 201405– COO before SVP BusDev + Operations before EVP Scientific Marketing)
  Person 2 Arnold, Katja (MC Services 201309 CIRO Executive Director before Wilex AG + CAT Consultants)
     


Proteros biostructures GmbH today announced that they have entered into a drug discovery research collaboration with Bayer Pharma AG (Bayer). The objective of the collaboration is to identify novel compounds for the treatment of cardiovascular diseases. Discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a 2 year period to meet predefined milestones, while Bayer would be responsible for further preclinical candidate optimization and clinical development. Proteros will receive R&D funding, downstream milestones, and royalties on sales of potential resulting commercial products.

The program is based on Proteros´ structure-guided lead discovery platform which combines structure analysis, medicinal chemistry and other discovery technologies to drive potency, selectivity, and safety of novel lead compounds.

Dr. Peter Reinemer, COO of Proteros, commented: “Regulatory membrane proteins are among the most challenging class of targets for structure guided drug discovery approaches. We are very pleased to partner with Bayer in this important initiative for potential new drug candidates for cardiovascular diseases”.


About Proteros biostructures

Proteros biostructures, located in Martinsried/Munich, is a privately-held company, focussing on protein-structure accelerated lead discovery. Proteros has established a unique and powerful platform for the integration of protein crystallography, biophysics – particularly kinetic and thermodynamic profiling –, tailor-made protein production for biophysical applications and Medicinal Chemistry. Proteros collaborates with more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. For more information, visit: www.proteros.de


Contacts:

Dr. Torsten Neuefeind, CEO
Proteros biostructures GmbH
Email: neuefeind@proteros.de

For Press enquiries:
Katja Arnold, MC Services AG
Email: katja.arnold@mc-services.eu
Phone: +49 89 210 228-0



   
Record changed: 2017-04-02

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Proteros (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translationl Medicine 2018 Würzburg Germany 600x100px




» top